IEX •
Healthcare •
Biotechnology •
Quote as of 06/12/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization2,647.23 mln
Float44.43 mln
Earnings Date08/19/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
59.22
Strong upside
Relative Strength
97
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-22.80
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Enliven Therapeutics is a drug development company working to create new treatments for cancer patients. Founded in 2019 and based in Boulder, Colorado, the company is currently running early-stage clinical trials for two experimental medicines ? one targeting a type of leukemia and another aimed at lung cancer and related tumors. Both treatments are designed as oral drugs that work by blocking specific proteins that drive cancer growth.
